StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Enbrel (etanercept by Year

Enbrel (etanercept — international outside U.S./Canada) — International reported YoY (%) (%)

Pfizer Enbrel (etanercept: -9.0% in FY2025, up 8.0 pts from a year earlier. That is the highest of the 9 years on record here.

Latest, FY2025
-9.0%
Period ended Dec 31, 2025
Change on a year earlier
+8.0 pts
-17.0% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Enbrel (Outside the U.S. and Canada) | 627 | 690 | (9%) | (9%) | — | — | — | 627 | 690 | (9%) | (9%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Pfizer Enbrel (etanercept (%), annual FY2017–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/enbrel-yoy-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.